September is Afib Awareness Month
37 million people worldwide suffer from atrial fibrillation. AtriCure’s EPi-Sense System is approved by the FDA for treatment of long-standing persistent Afib patients.
Top Workplaces 2023
Ready to work at a Top Workplace?
First Patient Treated in LeAAPS Clinical Trial
Safety & effectiveness study to evaluate if prophylactic left atrial appendage exclusion reduces occurrence of ischemic stroke or systemic embolism in cardiac surgery patients with elevated risk of stroke and no history of atrial fibrillation
Find a Specialist
Search for a qualified Hybrid AF Therapy treatment team
Pain Management Awareness Month
September is Pain Management Awareness Month. Cryo Nerve Block Therapy uses a unique freezing method to temporarily block pain signals from the nerves.
First Patient Treated in HEAL-IST™ Trial
Trial will evaluate the safety and effectiveness of AtriCure’s Isolator Synergy Clamp in conjunction with endocardial catheter ablation for the treatment of Inappropriate Sinus Tachycardia
0
Patients Served with Ablation Worldwide
0
AtriClip Devices Sold Worldwide
U.S. NEWS
AtriCure Reports Second Quarter 2023 Financial Results
REDUCING GLOBAL AFIB
What is Afib, and how does it affect heart performance?
CAREERS
Interested in joining our mission to reduce the global Afib epidemic?
THERAPY INNOVATION
Post-Operative Pain Management: Opening the Door to Some Cool Options
PM-US-0301J-0525-G
© 2023 Atricure, Inc. All Rights Reserved.
The EnCompass® Clamp is the newest innovation in bipolar RF ablation. EnCompass provides a magnetic guide, parallel closure, and uniform tissue pressure – while harnessing the technology we know works well.
The EnCompass® Clamp is the newest innovation in bipolar RF ablation. EnCompass provides a magnetic guide, parallel closure, and uniform tissue pressure – while harnessing the technology we know works well.
We're grateful for the skilled #SurgicalTechs who ensure safe and smooth operating rooms each day. Thank you for all you do! #SurgicalTechWeek
We're grateful for the skilled #SurgicalTechs who ensure safe and smooth operating rooms each day. Thank you for all you do! #SurgicalTechWeek
Do you have patients with inappropriate sinus tachycardia (IST)? If they’ve become refractory or intolerant to medications, they may be a candidate for the HEAL-IST Trial. For participation criteria and study details, visit https://bit.ly/clinical-heal-ist
Do you have patients with inappropriate sinus tachycardia (IST)? If they’ve become refractory or intolerant to medications, they may be a candidate for the HEAL-IST Trial. For participation criteria and study details, visit https://bit.ly/clinical-heal-ist
A metanalysis of CONVERGE and Real-World Data showed a 30-day major adverse event rate of 4% with a 95% confidence interval of 3-6% among more than 1,100 Hybrid Convergent Patients studied. See more #HybridAFTherapy data at https://bit.ly/47WQBk8
A metanalysis of CONVERGE and Real-World Data showed a 30-day major adverse event rate of 4% with a 95% confidence interval of 3-6% among more than 1,100 Hybrid Convergent Patients studied. See more #HybridAFTherapy data at https://bit.ly/47WQBk8
social media channels to keep updated on the latest at AtriCure.